Latest news with #neurologicalconditions
BBC News
26-07-2025
- Health
- BBC News
'Gloucester oxygen therapy centre is my lifeline'
A woman who has multiple sclerosis (MS) and attends an oxygen therapy centre has described the care she receives as "a lifeline".Jayne Lock, who lives in Gloucestershire, was diagnosed with MS in 1998. It is a condition that affects the brain and spinal cord and can have varying symptoms, including fatigue, vision problems and numbness. While it cannot currently be cured, treatment can often help manage Lock has been going to the charity Charcot Therapy Centre, in Gloucester, for exercises and treatment for 25 said: "Without it there would be a big black hole in my life. I'd be lost." The centre is celebrating 40 years of supporting people with neurological or long term offers a range of treatment and services, including hyperbaric oxygen therapy. Mrs Lock, who worked through all four of her pregnancies, said her MS diagnosis "took working life away" from her."It was horrendous because I'd not associated myself with MS, I didn't really know what it was," she said."A lot of people then sort of said 'oh, I'm so sorry that's what you've got'. So it made [me] feel even worse."But it's not a death sentence and that's important to recognise." Mrs Lock takes specialist exercise classes and has oxygen therapy at the centre."It's not like a hospital, it's not clinical. It's homely and gives me an uplift when I walk through the door," she oxygen therapy involves breathing pure oxygen in a pressurized increases oxygen levels in the blood, helping tissues heal more Lock explained there is a "strong social part" about receiving therapy at the centre."You can talk to other people that have got similar issues to you," she said."You're not all alone. You're not isolated and it's nice to be around people who understand." Rachael Evans, who has been CEO of the centre since 2014, said: "This is my passion. Like Jayne, people arrive, and then they don't go."This is about creating a place where people can come and be themselves."When Ms Evans joined Charcot there were about 36 people attending the centre. That number has now grown to more than 300."Not one person in this building is a number, everybody is an individual as we pride ourselves on getting to know everyone," she said."The door is open and it will always be open."
Yahoo
07-07-2025
- Business
- Yahoo
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today provided a quarterly update with respect to the Company's previously announced at-the-market equity program (the "ATM Program") launched on December 19, 2025. The ATM Program allows the Company to issue and sell common shares in the capital of the Company (the "Common Shares") to the public from time to time through Stifel Nicolaus Canada Inc. (the "Agent"), at the Company's discretion and subject to regulatory requirements. During the quarterly period ended June 30, 2025, the Company issued and sold 385,200 Common Shares under the ATM Program at a weighted average price of $2.95 per Common Share, for aggregate gross proceeds of $1,134,466. The Company paid cash placement fees of $22,689 to the Agent, resulting in aggregate net proceeds of $1,111,777. The Company announced as well that it granted 200,000 stock options (the "Options") to a director of the company. The Options are exercisable at a price of $3.55 per share and are exercisable for a period of five years and vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan. About NervGenNervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study clinical trial in spinal cord injury. Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated strong trends in a secondary endpoint assessing hand function. Complete analysis of the chronic cohort is ongoing. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on X and LinkedIn for the latest news on the company. Contacts Huitt Tracey, Investor Relationshtracey@ Bill Adams, Chief Financial Officerinfo@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking StatementsThis news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. Such forward-looking statements and information herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the issuance, sale and distribution of Common Shares under the ATM Program. Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: that the Company will receive the necessary regulatory approvals for the ATM Program; that the Company will be able to use the proceeds from the ATM Program as anticipated; our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, the Company being unable to use the proceeds from the ATM Program as anticipated, failure to receive the requisite regulatory approvals for the ATM Program, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on the Company's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Khaleej Times
01-07-2025
- Health
- Khaleej Times
'Worst headache in life': UAE doctors urge brain aneurysm screening as symptoms misunderstood
Doctors in the UAE are urging residents, especially those with a family history of neurological conditions, to screen for brain aneurysms and remain alert to early warning signs that are often brushed aside or misunderstood. The call for increased vigilance comes after Bollywood actor Salman Khan revealed in a candid moment on a popular talk show that he is dealing with brain aneurysm, trigeminal neuralgia, and arteriovenous (AV) malformation. The 59-year-old actor, known for his robust fitness routine and active lifestyle, left many of his fans stunned by the revelation. But Khan is not alone. From Game of Thrones star Emilia Clarke to actress Tamala Jones, who was just 23 when she survived a ruptured aneurysm in 1998, many well-known figures have shared their own experiences. They bring greater visibility to a condition that is often silent until it's too late. Hollywood actress Sharon Stone and singer-songwriter Neil Young have also spoken publicly about their near-fatal encounters with brain aneurysms. UAE-based neurologists are emphasising that awareness, early diagnosis, and regular check-ups could be lifesaving. 'An intracranial aneurysm, also known as a cerebral aneurysm, is a cerebrovascular disorder characterised by a localised dilation of a blood vessel in the brain due to a weakness in the vessel wall,' said Dr Mohamad Ahmad, neurology specialist at Saudi German Hospital, Sharjah. 'It can occur in any part of the brain but is most commonly found in the arteries of the Circle of Willis. The risk of rupture varies with the size and location of the aneurysm, with those in the posterior circulation being more prone to rupture. Screening is recommended for individuals with more than two first degree relatives with brain aneurysms or individual with genetic predisposition.' A 'silent threat' with global and local impact While brain aneurysms remain relatively rare, experts believe many people may unknowingly live with one. 'A 2023 systematic review of neurological disorders in the UAE mentions only one relevant source — the Global Burden of Disease (GBD) study — which estimates that the incidence of subarachnoid hemorrhage (often due to aneurysm rupture) in the UAE is between 11 and 13 per 100,000 people,' said Dr Anoop Narendran, neurologist at Medcare Royal, Dubai. 'Most global estimates range between 10 and 15 per 100,000, so the UAE sits comfortably within that typical range.' But the numbers alone don't capture the damage an undetected aneurysm can cause. That's why doctors here are stressing the importance of understanding the symptoms, particularly in the case of unruptured aneurysms. 'In unruptured cases, symptoms — if present — might include headaches, vision problems, eye pain, or even numbness in the face, drooping of eyes if the aneurysm is pressing on nearby nerves, or abnormal sounds in the ear (tinnitus),' explained Dr Ponnu Sankara Pillai, specialist neurologist at Aster Hospital Mankhool. 'A ruptured aneurysm typically causes a sudden, severe headache, often described as the 'worst headache of one's life,' accompanied by nausea, vomiting, loss of consciousness, or seizures. It's a neurological emergency requiring immediate attention,' he added. Healthcare professionals also note that lifestyle factors like high salt intake, sedentary habits, and stress may further influence vascular health. At-risk individuals Doctors say certain individuals should take extra precautions, particularly those above 40 with a history of uncontrolled hypertension, heavy smoking, or sudden, unexplained deaths in the family. 'In the UAE, while comprehensive population-level data is limited, we do see brain aneurysms with comparable frequency to global estimates,' added Dr Pillai. 'Those presenting with unrelenting headache, tinnitus, double vision, facial droop, or any neurological symptoms — especially with family history — should consider proactive imaging and counseling.'
Khaleej Times
28-06-2025
- Health
- Khaleej Times
Bollywood star Salman Khan reveals struggle with brain tumour; how to spot illness
Recently, Bollywood star Salman Khan revealed that he is battling multiple serious illnesses at a comedy show. The superstar said that he is "still working" and "breaking [his] bones". On The Great Indian Kapil Show, the star said, "I'm working despite having trigeminal neuralgia, there's an aneurysm in the brain, yet I'm still working. There is also an AV malformation, and still, I'm carrying on," he said. This confession came shortly after his performance at an award show, where many commented on his appearance. Brain aneurysms, arteriovenous malformations (AVMs), and trigeminal neuralgia are serious neurological conditions that can lead to severe complications. Here's more on the diseases he mentioned: Brain aneurysm: A brain aneurysm is a bulge or ballooning in a blood vessel in the brain, caused by a weak spot in the vessel wall. If the aneurysm ruptures, it can lead to a hemorrhagic stroke, which is life-threatening. Common symptoms: Unruptured aneurysm: Headache (localised or persistent) Vision problems (blurred or double vision) Pain above or behind the eye Dilated pupils Difficulty speaking or concentrating Weakness or numbness on one side of the face Ruptured aneurysm (medical emergency): Sudden, severe headache ('thunderclap headache') Nausea and vomiting Stiff neck Sensitivity to light Loss of consciousness Seizures Arteriovenous malformation (AVM): An AVM is a tangle of abnormal blood vessels connecting arteries and veins in the brain. It disrupts normal blood flow and oxygen delivery and can cause hemorrhaging if it ruptures. Common symptoms: Headaches (may vary in intensity and pattern) Seizures Muscle weakness or numbness, often on one side Difficulty speaking or understanding language Vision loss or disturbances Unsteadiness or coordination issues Sudden onset of neurological symptoms if ruptured (stroke-like symptoms) Trigeminal neuralgia: Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from your face to your brain. Even mild stimulation of the face may trigger intense pain. Common symptoms:
BBC News
21-06-2025
- General
- BBC News
Special school in Dormansland rated outstanding by Ofsted
A residential special school in Surrey has been rated "outstanding" by Ofsted, with inspectors praising the "safe, vibrant and inclusive environment" for Piers School in Dormansland, near Lingfield, supports children and young people aged 4 to 19 with neurological conditions such as epilepsy, autism and complex residential provision, which caters for students aged 12 to 19, has been commended by Ofsted following an inspection in Meakings, head of residential services, said the rating was "testament to the passion, professionalism, and commitment of our team". The report noted a "culture of celebrating uniqueness, promoting high expectations and focusing on future planning".St Pier School has a "waking day cirriculum", which aims to ensure that learning extends beyond the school day, which was highlighted as a particular also praised the role played by therapists who work directly with students to embed "communication, emotional self-regulation and sensory strategies into students' daily routines".The school was rated "outstanding" in terms of students' overall experience and progress, and with respect to how well students were helped and effectiveness of leaders and managers was rated as "good", with inspectors acknowledging the progress made since the previous inspection in 2024.
